Business Monitor International


France Pharmaceuticals & Healthcare Report

Published 04 December 2014

  • 132 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
France Pharmaceuticals & Healthcare Report

BMI View:   D espite the French government partial ly abandoning fiscal deficit targets in   its 2015 budget , cost - containment measures will continue to weigh on the pharmaceuticals and healthcare sector for   the foreseeable future . The government 's strategy of emphasis ing preventive care and improved access to doctors will likely avoid long-term costs by reducing the burden or risks associated with unchecked conditions . Meanwhile, it will also sustain access to medicines, including prescription drug s , provided that French healthcare and medicine consumption patterns remain high.

Headline Expenditure Projections

  • Pharmaceuticals: EUR33.94bn (USD44.80bn) in 2013 to EUR33.06bn (USD44.29bn) in 2014; -2.6% in local currency terms and -1.1% in US dollar terms.

  • Healthcare: EUR245.28bn (USD323.77bn) in 2013 to EUR252.33bn (USD338.13bn) in 2014; +2.9% in local currency terms and 4.4% in US dollar terms.

Risk/Reward Index

In Q115 France maintains an overall Risk/Reward Index (RRI) score of 71.7 out of the maximum 100 points. However, this has shifted downward the country's ranking position in terms of attractiveness to pharmaceutical investors from third in Q414 to fourth in Q115 out of 15 markets in Western Europe. An upward revision to the UK market score is the main driver underlying ranking variation. The French market Rewards' indices, including market growth rate, remain less attractive than its Risk score.

Key Trends And Developments

October

  • Multinational drugmaker  Sanofi reported Q314 yearly financial data: a 5.1% increase in revenues to EUR8.78bn (USD14.14bn), a 9.4% increase in net income to EUR1.94bn (USD3.13bn) and a 10.3% increase in earnings per share to EUR1.47 (2.37USD) - boosted by the favourable impact of vaccine (+11.2%), animal health (+12.7%) and  Genzyme (+24.6%) sales. However, investor sentiment sank  following the company's announcement that growth of its diabetes treatments (accounting for a fifth of...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (France 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (France 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (France 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (France 2010-2018)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (France 2010-2018)
22
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (France 2010-2018)
23
France Generic Drug Market Forecast
24
Table: Generics Drug Market Indicators, Historical Data And Forecasts (France 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (France 2010-2018)
31
Pharmaceutical Trade Forecast
32
Table: Pharmaceutical Trade Data And Forecasts (France 2012-2018)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (France 2012-2018)
34
Other Healthcare Data
34
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
36
Economic Analysis
36
Macro Outlook
36
Real GDP By Expenditure Breakdown
37
Risks To Outlook
40
Table: France - Economic Activity
41
Industry Risk Reward Ratings
42
Western Europe Risk/Reward Ratings
42
France Risk/Reward Ratings
47
Rewards
47
Risks
47
Market Overview
49
Industry Trends And Developments
50
Epidemiology
50
Prescription Drugs
51
Healthcare Financing
52
Public Hospitals
54
Table: Hospital Activity, 2005-2009
55
Table: Hospital Activity in Short-Stay Units, 2009
56
Table: Diagnostic & Therapeutic Procedures Performed in Public & Private Hospitals, 2009
57
Table: Regional Ranking Of Projected Physicians, 2017
59
Table: Projected Physicians, 2012-2017
59
Table: Medical Personnel, 2005-2010
60
Generic Drugs
60
Research & Development
61
Biotechnology
63
Clinical Trials
66
Regulatory Development
68
Intellectual Property Issues
70
Pricing & Reimbursement
71
Table: France Reimbursement Categories
71
Biosimilars
74
OTC Medicines
79
Competitive Landscape
80
Pharmaceutical Sector
80
Foreign Industry
82
Pharmaceutical Distribution
83
Pharmaceutical Retail Sector
84
Company Profile
86
Sanofi
86
Servier
96
Ipsen
101
Pfizer
106
GlaxoSmithKline
109
Novartis
112
Merck & Co
115
Demographic Forecast
117
Table: France's Population By Age Group, 1990-2020 ('000)
118
Table: France's Population By Age Group, 1990-2020 (% of total)
119
Table: France's Key Population Ratios, 1990-2020
120
Table: France's Rural And Urban Population, 1990-2020
120
Glossary
121
Methodology
123
Pharmaceutical Expenditure Forecast Model
123
Healthcare Expenditure Forecast Model
123
Notes On Methodology
124
Risk/Reward Ratings Methodology
125
Ratings Overview
126
Table: Pharmaceutical Risk/Reward Ratings Indicators
126
Indicator Weightings
127

The France Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's France Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the France pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for France, to test other views - a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.
  • Target business opportunities and risks in the French pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in France.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc